Abstract
All interferons consistently cause a variety of symptoms and signs in man which are interpreted as “toxic” effects because they are unpleasant, but may reflect the normal pathophysiologic effects of high levels of endogenous interferon produced acutely during virus infections or chronically during active autoimmune processes. Many of the effects appear to be non-specific and are probably in part mediated by inflammatory prostaglandin synthesis. Toxic effects may be augmented by impurities in interferons derived from any source. They may be reduced by giving prostaglandin antagonists or steroids or by giving interferons in the evening. Both subjectively and objectively, acute febrile responses and associated symptoms are often reduced with repeated dosing, but tend to be replaced by chronic fatigue and malaise. Idiosyncratic responses such as glomerulonephritis, thrombocytopenia or thyroid disease may involve autoimmune processes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Falcoff, E., Falcoff, R., Fournier, F. and Chany, C. Ann. Inst. Pasteur 111: 562–584, 1966.
Strander, H., Cantell, K., Carlstrom, G. and Jakobsson, P.J. Natn. Cancer Inst. 51: 733–742, 1973.
Ingimarrson, S., Cantell, K. and Strander, H. J. Infect. Dis. 140: 560–563, 1979.
Scott, G., Stewart, W.E.11, Tyrrell, D.A.J., Cantell, K. and Edy, V. J. Interferon Res. 1: 79–86, 1980.
Priestman, T. J. Lancet 2: 113–118, 1980.
Scott, G.M., Secher, D.S., Flowers, D., Bate, J., Cantell, K. and Tyrrell, D.A.J. Br. Med. J. 282: 1345–1348, 1981.
Spiegel, R.J. Semin. Oncol. 13: 89–101, 1986.
Jones, G.J. and Itri, L.M. Cancer 57: 1709–1715, 1986.
Sama, G., Pertcheck, M., Figlin, R. and Ardalan, B. Cancer Treat. Rep. 70: 1365–1372, 1986.
Kurzrock, R., Quesada, J.R., Rosenblum M.G., Sherwin, S.A. and Gutterman, J.U. Cancer Treat. Rep. 70: 1357–1364, 1986.
Heron, I. and Berg, K. Nature 274: 508–510, 1978.
Stringfellow, D.A. Science 201: 376–378, 1978.
Scott, G.M., Ward, R.J., Wright, D.J., Robinson, J.A., Onwubalili, J.K. and Gauci, C.L. Antimicrob. Agents Chemother. 23: 589–592, 1983.
Jacobs, L., Salazar, A.M., Herndon, R., Reese, P.A., Freeman, A., Josefowicz, R., Cuetter, A., Husain, F., Smith, W.A., Ekes, R. and O’Malley, J.A. Lancet 2: 1411–1413, 1986.
Hawkins, M.J., Borden, E.S. and Edwards B.S. J. Clin. Oncol. 2: 221–226, 1984.
Oldham, R.R. Science 219: 902, 1982.
Blalock, J.E. and Stanton G.J. Nature 283: 406, 1980
Rohatiner, A.Z.S., Prior, P.F., Burton, A.C., Smith, A.T., Balkwill, F.R. and Lister, T.A. Br. J. Cancer 47: 419–422, 1983
Yaron, M., Yaron, I., Gurari-Rotman, D., Revel, M., Lindner, H. and Zor, V. Nature 267: 457–459, 1977.
Fuse, A., Mahmud, I., and Kuwata, T. Cancer Res. 42: 3209–3214, 1982.
Dinarello, CA., Bernheim, H.A., Duff, G.W., Hung, V.L., Nagabushan, T.C., Hamilton, N.C. and Coceani, F. J. Clin. Invest. 74: 906–913, 1984.
Lucero, M.A., Magdelenat, H., Fridman, W.H., Pouillart, P., Billiau, A., Cantell, K. and Falcoff, E. Eur. J. Cancer Clin. Oncol. 18: 243–251, 1982.
Abrams, P.G., McClamrock, E. and Foon, K.A. N. Engl. J. Med. 312: 443–444, 1985.
Merigan, T.C., Sikora, K., Breeden, J., Levy, R., and Rosenberg, S.A. N. Engl. J. Med. 299: 1449–1453, 1978.
Finter, N.B., Woodroffe, J. and Priestman, T. Nature 298: 301, 1982.
Feldberg, W. and Scott, G. J. Physiol. 355:28P, 1984
Calvet, M-C. and Gresser, I. Nature 278:558–560, 1979
Elfenbeim, D.S., Murphy, P.A., Chesney, P.J., Seto, D.S. and Carver, D.H. J. gen. Virol. 42: 185–187, 1979
Hayden, F.G., Mills, S.E. and Johns, M.E. J. Infect. Dis. 148: 914–921, 1983.
Hayden, F.G., Innes, D.J., Mills, S.E. and Levine, P.A. In: The Biology of the Interferon System 1986 (Eds. K. Cantell and H. Schellekens), Martinus Nijhoff, Dordrecht, 1987, pp.449–456.
Mirro, J., Kalwinsky, D., Whisnant, J., Weck, P. Chesney, C. and Murphy, S. Cancer Treat. Rep. 69: 315–317, 1985.
Broxmeyer, H., Lu, L., Platzer, E., Feit. C., Juliano L. and Rubin, Y. J. Immunol. 131: 1300–1313, 1983
Kataoka, T., Ohhashi, F., Sukurai, Y., and Ida, N. Cancer Chemother. Pharmacol. 9: 75–80, 1982
Mannering, G.J., Renton, K.W., El Azhary, R., and Deloria L.B. Ann. N.Y. Acad. Sci. 350: 314–331, 1980.
Gresser, I., Tovey, M.G., Bandu, M.T., Maury, C. and Brouty-Boye, D. Nature 258: 76–78, 1975.
Kauppila, A., Cantell, K., Janne, O., Kokko, E. and Vikho, R. Int. J. Cancer 29: 291–294, 1982.
Cantell, K., Enholm, C., Mattila, K. and Kostianen, E. N. Engl. J. Red. 302: 1032–1033, 1980
Smedley, H., Katrak, M., Sikora, K. and Wheeler, T. Br. Med. J. 286: 262–264, 1983.34.
Rohatiner A.Z., Balkwill, F.R., Griffin, D.B., Malpas, J.S. and Lister, T.A. Cancer Chemother. Pharmacol. 9: 97–102, 1982.
Cheeseman, S.H., Rubin, R., Stewart, J., Tolkoff-Rubin, N., Cosimi, A., Cantell, K., Gilbert, J., Winkle, S., Herrin, J., Black, P., Russell, P. and Hirsch, M. N. Engl. J. Med. 300: 1345–1349, 1979.
Kramer, P., Ten Kate, F., Bijnen, A. and Weimar, W. Lancet 1: 989–990, 1984.
Averbuch, S.D., Austin, H.A., Sherwin, S.A., Antonovych, T., Bunn, P.A. and Longo, D.L. N. Engl. J. Med. 300:32–35, 1984.
Herrman, J. and Gabriel, F. N. Engl. J. Med. 316: 112–113, 1987
Fentiman, I.S., Thomas, B.S., Balkwill, F.R., Rubens, R.D. and Hayward, J.L. Lancet 1: 1166, 1985.
Burman, P., Totterman, T.H., Oberg, K. and Karlsson, F.A. J. Clin. Endocrinol. Metab. 63: 1086–1090, 1986.
Bevan, P.C. Lancet 2: 561, 1985.
Sangster, G., Kaye, S.B., Caiman, K.C. and Toy, J.L. Eur. J. Clin. Oncol. 19: 1647–1649, 1983.
Mogensen, K.E., Daubas, P., Gresser, I., Sereni, D. and Varet, B. Lancet 2: 1227–1228, 1981.
Vallbracht, A., Treuner, J., Manncke, K.H. and Niethammer, D. J. Interferon Res. 2: 107–110, 1982.
Krown, S.E., Real, F., Cunningham-Rundles, S., Mysowski, P.L., Koziner, B., Fein, S., Mittleman, A., Oettgen, H.F. and Safai, B. N. Engl. J. Med. 308: 1071–1076, 1983.
Quesada, J.R. and Gutterman, J.U. J. Natl. Cancer Inst. 70: 1041–1046, 1983.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Scott, G.M.S. (1988). Toxic Effects. In: Revel, M. (eds) Clinical Aspects of Interferons. Developments in Medical Virology, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1737-1_19
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1737-1_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8977-7
Online ISBN: 978-1-4613-1737-1
eBook Packages: Springer Book Archive